BridgeBio Oncology Therapeutics
BBOTClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
— — — —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
— ($35.05M) ($121.20M) ($39.80M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($1.12M) ($14.13M) ($24.62M) ($6.38M)
Operating Income / (Loss)
($1.12M) ($49.18M) ($145.82M) ($46.18M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
$2.07M — — —
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
$2.04M $4.42M $11.78M $4.07M
Income Tax Provision / (Benefit)
$0.00M $0.00M $0.00M —
NET INCOME / (NET LOSS)
($28.43M) ($44.76M) ($134.04M) ($42.11M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$0.7M$408.7M$373.7M$52.7M
Short-Term Marketable Investments
// --$59.5M$51.8M$199.6M
Total Liquid Cash Resources
$0.7M$468.3M$425.5M$252.3M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$0.1M$7.5M$6.5M$14.1M
Total Current Assets
$0.9M$476.0M$432.4M$266.5M
Property, Plant and Equipment, Net
// --$0.8M$1.0M$0.9M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$197.4M$484.8M$448.4M$417.6M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
// --$3.6M$1.4M$12.1M
Accrued Expenses & Clinical Liabilities
// --// --// --// --
Total Current Liabilities
$2.6M$35.7M$35.0M$43.3M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$5.5M$2.4M$2.2M$2.1M
Total Liabilities Block
$8.1M$38.1M$37.3M$45.4M
Total Stockholders' Equity
$-7.3M$446.7M$411.1M$372.3M
TOTAL LIABILITIES & EQUITY
$0.9M$484.8M$448.4M$417.6M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
0.33x 13.33x 12.34x 6.16x
R&D Expenditure Flow
// --$83.1M$121.2M$39.8M
Net Income / (Loss)
($28.43M) ($44.76M) ($134.04M) ($42.11M)
Depreciation & Amortization
— $0.20M $0.28M $0.07M
Stock-Based Compensation
$0.04M $2.93M $5.87M $3.87M
Change in Accounts Receivable
— — — —
Change in Prepaid Assets / Expenses
$0.06M $4.37M $3.42M $7.53M
Change in Payables & Clinical Accruals
$2.40M $0.58M ($1.84M) $10.69M
Other Operating Source / (Use) Changes
$24.90M ($34.97M) $12.42M ($15.97M)
Net Cash from Operating Activities
($1.03M) ($71.66M) ($113.89M) ($35.92M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
— ($0.53M) ($0.61M) ($0.02M)
Purchases of Marketable Securities
— ($62.88M) ($83.92M) ($311.64M)
Maturities & Sales of Investments
— $128.98M $157.86M $26.26M
Net Cash from Investing Activities
— $65.56M $73.33M ($285.41M)
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
— $120.90M $112.30M $112.30M
Net Cash from Financing Activities
— $383.99M $383.40M $0.29M
NET CONSOLIDATED CHANGE IN CASH
— — — —
Clinical Trials Registry
Registry ID
Phase / Asset
Status